 The goal of the Anticancer Fund is to expand cancer treatment options by supporting clinical trials with repurposed drugs and other interventions with no or low commercial value for the pharmaceutical industry. |
|
Pan Pantziarka |
Pan has been working with the Anticancer Fund since December 2013 and is currently Program Director for Drug Repurposing. He is also the coordinator of the ReDO project. Pan is the co-founder of the George Pantziarka TP53 Trust, a UK-based charity that supports families afflicted with Li Fraumeni Syndrome, a rare genetic condition that pre-disposes sufferers to cancer. |
Gauthier Bouche |
Gauthier is the clinical research director of the Anticancer Fund. Gauthier holds an MD and a Master’s of Public Health. His interest in drug repurposing came after reading several articles reporting striking results in cancer patients with repurposed drugs. |
| Lydie Meheus  |
Lydie is the Managing Director of the Anticancer Fund. She holds a PhD in Protein Biochemistry and acted as VP R&D in the biopharmaceutical industry. Lydie supervises the work done by Gauthier and Pan for the ReDO project. |
 GlobalCures is a non-profit medical research organization dedicated to curing patients with cancer and other diseases by rapidly promoting clinical research on scientifically promising, readily available and cost-effective treatments. Our strategy is to repurpose existing drugs, currently being overlooked for cancer use, due to lack of profitability. |
|
Vidula Sukhatme |
Vidula is co-founder and Chief Executive Officer of GlobalCures. She holds an MS in mathematics from Northeastern University and an MS from the Harvard School of Public Health in epidemiology. She has 20 years of experience in information systems in a healthcare environment. |
Vikas Sukhatme |
Vikas received a doctorate in physics (ScD) from MIT and an MD from Harvard Medical School. He is a physician engaged in both basic science and patient-oriented research at Emory University in Atlanta, where he is Woodruff Professor, Dean of Emory School of Medicine and Chief Academic Officer of Emory Healthcare. Previously at Harvard Medical School, he was the Victor J. Aresty Professor of Medicine and Chief Academic Officer at Beth Israel Deaconess Medical Center, Boston. His primary interest is in cancer but his research has spanned such diverse areas as toxemia of pregnancy and sepsis. |
